United Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $15.5B
- Website
- http://www.unither.com
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 243
- Registration Number
- NCT02633293
- Locations
- πΊπΈ
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
πΊπΈUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
πΊπΈCleveland Clinic, Cleveland, Ohio, United States
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
- Conditions
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 326
- Registration Number
- NCT02630316
- Locations
- πΊπΈ
Wellstar Medical Group - Pulmonary Medicine, Marietta, Georgia, United States
πΊπΈJohns Hopkins University Pulmonary and Critical Care Medicine, Baltimore, Maryland, United States
πΊπΈPenn Medicine University City, Philadelphia, Pennsylvania, United States
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- United Therapeutics
- Registration Number
- NCT02603068
- Locations
- πΊπΈ
Emory University Hospital, Atlanta, Georgia, United States
πΊπΈCLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC, Pittsburgh, Pennsylvania, United States
πΊπΈBanner University Medical Center Phoenix Advanced Lung Disease, Phoenix, Arizona, United States
Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT02318758
- Locations
- πΊπΈ
PPD International, Austin, Texas, United States
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02279745
- Locations
- πΊπΈ
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
π¦πΊSt Vincent's Hospital, Fitzroy, Victoria, Australia
π§π¬Multiprofile Hospital for Active Treatment "National Heart Hospital" EAD, Clinic of Cardiology, Sofia, Bulgaria
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 61
- Registration Number
- NCT02279160
- Locations
- πΊπΈ
UT Southwestern, Dallas, Texas, United States
πΊπΈBoston University Medical Center, Boston, Massachusetts, United States
πΊπΈUniversity of Cincinnati, Cincinnati, Ohio, United States
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT02276872
- Locations
- πΊπΈ
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
πΊπΈChildren's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
- Conditions
- Interventions
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT02261883
- Locations
- πΊπΈ
Stanford Children's Hospital, Palo Alto, California, United States
πΊπΈJohns Hopkins Hospital, Baltimore, Maryland, United States
πΊπΈArkansas Children's Hospital, Little Rock, Arkansas, United States
Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- United Therapeutics
- Registration Number
- NCT02149095
- Locations
- πΊπΈ
PPD Development, Austin, Texas, United States
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
- Conditions
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT01934582
- Locations
- πΊπΈ
University of Rochester Medical Center, Rochester, New York, United States